Xeris Biopharma Holdings, Inc.
XERS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867096
In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 8 sales; 242 institutions reported holding it in 13F filings for Q2 2026, worth $857.1M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Xeris Biopharma Holdings, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 201
- +3 vs. Q1 2025
- Shares held
- 90.6M
- +2.96M (+3.4%) vs. Q1 2025
- Total value
- $422.9M
- −$58.0M (−12.1%) vs. Q1 2025
- New holders
- 26
- 79 more added
- Sold out
- 23
- 59 more reduced
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XERS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 242 | $857.1M |
| Q1 2026 | 239 | $610.3M |
| Q4 2025 | 227 | $792.0M |
| Q3 2025 | 231 | $789.3M |
| Q2 2025 | 201 | $422.9M |
| Q1 2025 | 199 | $480.9M |
| Q4 2024 | 162 | $222.2M |
| Q3 2024 | 144 | $182.2M |
| Q2 2024 | 135 | $136.6M |
| Q1 2024 | 142 | $133.7M |
| Q4 2023 | 120 | $140.8M |
| Q3 2023 | 111 | $102.3M |
| Q2 2023 | 105 | $146.7M |
| Q1 2023 | 92 | $80.6M |
| Q4 2022 | 97 | $71.6M |
| Q3 2022 | 101 | $89.3M |
| Q2 2022 | 103 | $91.3M |
| Q1 2022 | 103 | $129.2M |
| Q4 2021 | 92 | $120.2M |
| Q3 2021 | 71 | $42.9M |
| Q2 2021 | 94 | $114.9M |
| Q1 2021 | 103 | $149.7M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Xeris Biopharma Holdings, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11,536,321 | $53.9M | 0.00% | +741,720+6.9% | Added |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −1,347,859−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −239,600−100.0% | Sold out |
| Semanteon Capital Management, LP | 0 | $0 | 0.00% | −156,191−100.0% | Sold out |
| Panagora Asset Management Inc | 0 | $0 | 0.00% | −145,526−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −134,016−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −81,112−100.0% | Sold out |
| Corebridge Financial, Inc. | 0 | $0 | 0.00% | −68,698−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −59,300−100.0% | Sold out |
| Mach-1 Financial Group, Inc. | 0 | $0 | 0.00% | −52,530−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −41,290−100.0% | Sold out |
| Goldstein Advisors, LLC | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −34,454−100.0% | Sold out |
| Caxton Associates LLP | 0 | $0 | 0.00% | −30,938−100.0% | Sold out |
| Gateway Wealth Partners, LLC | 0 | $0 | 0.00% | −16,800−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −16,769−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −16,205−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −15,730−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −15,348−100.0% | Sold out |
| Oxford Asset Management LLP | 0 | $0 | 0.00% | −13,901−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −11,500−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −11,182−100.0% | Sold out |
| FORA Capital, LLC | 0 | $0 | 0.00% | −11,017−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −65−100.0% | Sold out |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |